X0306 4 2015-08-28 0001003642 IMPAX LABORATORIES INC IPXL 0001025714 MARKBREITER MICHAEL C/O IMPAX LABORATORIES, INC. 30831 HUNTWOOD AVENUE HAYWARD CA 94544 1 Common Stock 2015-08-28 4 M 0 8000 17.99 A 16200 D Common Stock 2015-08-28 4 S 0 8000 42.48 D 8200 D Common Stock 2015-08-31 4 M 0 10000 20.90 A 18200 D Common Stock 2015-08-31 4 S 0 10000 41.39 D 8200 D Common Stock 2015-08-31 4 M 0 10000 20.30 A 18200 D Common Stock 2015-08-31 4 S 0 10000 41.39 D 8200 D Stock Option (Right to Buy) 17.99 2015-08-28 4 M 0 8000 0 D 2023-05-15 Common Stock 8000 4000 D Stock Option (Right to Buy) 20.90 2015-08-31 4 M 0 10000 0 D 2022-05-23 Common Stock 10000 0 D Stock Option (Right to Buy) 20.30 2015-08-31 4 M 0 10000 0 D 2020-05-26 Common Stock 10000 0 D The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $42.29 to $42.71 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.39 to $42.75 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.39 to $42.75 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Of the 12,000 shares underlying the options, 8,000 of the shares subject to the option are fully vested and exercisable. 100% of the shares subject to the option are fully vested and exercisable. The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person. /s/ Mark A. Schlossberg, by Power of Attorney 2015-09-01